HIMS 2X Long ETF

What a week overall.. $Merck(MRK.US), $Cheesecake Factory(CAKE.US), $Hims & Hers Health(HIMS.US), $GLD, $SLV, $Freeport Mcmoran(FCX.US), to name a few.. I have $Merck(MRK.US), but missed $Moderna(MRNA.US).

Have a happy $Hims & Hers Health(HIMS.US) weekend if you know what I mean.. I am talking about the trade and chart😂

$Hims & Hers Health(HIMS.US) | Barclays 𝗺𝗮𝗶𝗻𝘁𝗮𝗶𝗻𝘀 𝗢𝘃𝗲𝗿𝘄𝗲𝗶𝗴𝗵𝘁 on 𝗛𝗶𝗺𝘀 & 𝗛𝗲𝗿𝘀 𝗛𝗲𝗮𝗹𝘁𝗵, cuts PT to $𝟯𝟱 from $𝟯𝟵

Analyst sees faster revenue growth but near-term margin pressure from investments supporting growth.

$Hims & Hers Health(HIMS.US) | Canaccord 𝗿𝗲𝗶𝘁𝗲𝗿𝗮𝘁𝗲𝘀 𝗕𝘂𝘆 on 𝗛𝗶𝗺𝘀 & 𝗛𝗲𝗿𝘀 𝗛𝗲𝗮𝗹𝘁𝗵, maintains PT at $𝟰𝟬

Analyst sees strong Q2 results and momentum in newer specialties, international markets, and AI supporting the reiterated Buy.

For $Hims & Hers Health(HIMS.US) earnings tonight after the bell, the cleanest near-term options estimate I’m seeing is about a ±14.4% implied earnings move for the Aug. 14 weekly expiration.

Using $31.72 spot:

Implied move: ≈ ±$4.57

Upside implied target: ≈ $36.29

Downside implied target: ≈ $27.15

The upper Bollinger Band is $36.83, basically sitting right around the bullish implied-move zone. On the downside, $27.15 lands almost directly on the 100-day MA at $27.76.

200-day MA at $29.64 would be the first major downside technical level before that.

$Hims & Hers Health(HIMS.US) Earnings Map

$39.05 — July swing high / breakout target

$36.30–$36.85 — implied upside + upper Bollinger Band

$31.72 — current price

$31.33 — 50 DMA

$31.10 — 21 EMA

$30.76 — 8 EMA

$29.64 — 200 DMA

$27.15–$27.76 — implied downside + 100 DMA

The setup is pretty clean technically: $36–37 is the expected bullish landing zone; $27–28 is the bearish landing zone.

A move through either side would represent an earnings move beyond what the options market is broadly pricing.

📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $Hims & Hers Health(HIMS.US) Hims & Hers Launches AI-Powered Hers App for Women's Weight Loss Care

👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:

➤ 𝗛𝗶𝗺𝘀 & 𝗛𝗲𝗿𝘀 unveils an AI-integrated 𝗛𝗲𝗿𝘀 app experience.

➤ AI, providers, and care teams collaborate within a single conversation thread.

➤ AI uses patient history, treatment plans, and progress for personalized support.

➤ Licensed providers retain authority over all prescriptions and clinical decisions.

➤ Company introduces a 𝗛𝗲𝗿𝘀 𝘀𝗺𝗮𝗿𝘁 𝘀𝗰𝗮𝗹𝗲 at no additional cost.

➤ Smart scale syncs weight and 𝗚𝗟𝗣-𝟭 progress directly to the app.

➤ Providers, care teams, and AI can access synced patient progress data.

➤ Company describes the platform as a "𝗳𝗶𝗿𝘀𝘁-𝗼𝗳-𝗶𝘁𝘀-𝗸𝗶𝗻𝗱" AI-integrated care experience.

➤ Hims & Hers plans to expand AI capabilities to the 𝗛𝗶𝗺𝘀 app and additional health categories.

👉 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀:

➤ Deepens AI integration across digital healthcare and chronic weight management.

➤ Could improve care coordination between patients, AI, and licensed providers.

➤ Strengthens Hims & Hers' competitive position in AI-enabled telehealth.

➤ Expands the company's ecosystem beyond medication into connected health devices.

👉 𝗘𝘅𝗽𝗲𝗿𝘁 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀:

𝗠𝗼 𝗘𝗹𝘀𝗵𝗲𝗻𝗮𝘄𝘆, Chief Technology Officer at Hims & Hers:

"This new experience on the Hers app embeds intelligence at every step of the care experience. It knows each woman's treatment plan, delivers support unique to her, and brings a provider into the conversation when clinical judgment is needed."

𝗝𝗲𝘀𝘀𝗶𝗰𝗮 𝗦𝗵𝗲𝗽𝗵𝗲𝗿𝗱, 𝗠𝗗, 𝗙𝗔𝗖𝗢𝗚, Chief Medical Officer:

"the clinical oversight, lifestyle guidance, and support a woman receives between appointments can matter just as much as the treatment itself."

📢 𝗝𝗨𝗦𝗧 𝗜𝗡: Novo Nordisk Raises 2026 Outlook on Stronger GLP-1 Sales Expectations - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)

👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:

➤ 𝗡𝗼𝘃𝗼 𝗡𝗼𝗿𝗱𝗶𝘀𝗸 raised its full-year 𝟮𝟬𝟮𝟲 adjusted guidance.

➤ Higher outlook reflects stronger expected 𝗚𝗟𝗣-𝟭 product sales.

➤ Adjusted sales guidance improved to 𝟬% 𝘁𝗼 -𝟲% at CER.

➤ Previous adjusted sales outlook was -𝟰% 𝘁𝗼 -𝟭𝟮% at CER.

➤ Adjusted operating profit guidance improved to 𝟬% 𝘁𝗼 -𝟲% at CER.

➤ 𝗤𝟮 adjusted sales reached 𝗗𝗞𝗞 𝟳𝟴,𝟰𝟴𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻, up 𝟳% at CER.

➤ 𝗤𝟮 adjusted operating profit totaled 𝗗𝗞𝗞 𝟯𝟯,𝟯𝟴𝟵 𝗺𝗶𝗹𝗹𝗶𝗼𝗻, up 𝟭𝟭% at CER.

➤ Results exclude one-time impacts from the U.S. 𝟯𝟰𝟬𝗕 𝗗𝗿𝘂𝗴 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗣𝗿𝗼𝗴𝗿𝗮𝗺.

➤ 𝗤𝟮 included 𝗗𝗞𝗞 𝟲.𝟯 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 in non-cash impairment charges.

👉 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀:

➤ Improved guidance signals stronger-than-expected demand for 𝗚𝗟𝗣-𝟭 therapies.

➤ Higher outlook may strengthen investor confidence in Novo Nordisk's earnings trajectory.

➤ Excluding one-time items provides a clearer view of underlying operating performance.

$Hims & Hers Health(HIMS.US) = >>>>triple-bottom structure in Williams %R, with three separate tests near the −100 extreme-oversold zone in late July.

Earnings are August 10th with 100% Implied Volatility.

More importantly, price appears to have made lower lows while Williams %R held roughly equal lows.

That creates a potential bullish momentum divergence: selling pressure pushed price lower, but the oscillator did not deteriorate further.

What confirms the reversal:

$Hims & Hers Health(HIMS.US) at $30.29 and reclaimed:

8 EMA: $29.18

200-day MA: $30.22

The next confirmation zone is tight:

50-day MA: $30.63

21 EMA: $30.91

A daily close above $30.90–$31.00 would strengthen the reversal setup. Then the next upside level is the Bollinger midpoint near $32.44.

Risk levels

The pattern weakens if price loses $27.57–$27.77 again. The lower Bollinger Band around $25.42 is the deeper support level.

Bottom line: Triple bottom in the oscillator—yes. Bullish divergence—likely.

But the price reversal becomes much more credible only after $Hims & Hers Health(HIMS.US) clears and holds $31, followed by $32.40.

@Liathetrader @alc2022 @NighthawkTradez @himshouse

$Hims & Hers Health(HIMS.US)

I love Hims because they turned healthcare into a brand people actually open on their phone. Weight loss, hair, hormones, the whole DTC stack. Next catalyst is the FDA peptide meeting. That’s why I am waiting. Consumer demand is another aspect.

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: EU Approves Novo Nordisk's Oral Wegovy for Obesity Treatment - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US)

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐂𝐨𝐦𝐦𝐢𝐬𝐬𝐢𝐨𝐧 approves 𝐨𝐫𝐚𝐥 𝐖𝐞𝐠𝐨𝐯𝐲 𝟐𝟓 𝐦𝐠.

➤ Approval covers adults with 𝐨𝐛𝐞𝐬𝐢𝐭𝐲 or overweight with comorbidities.

➤ Oral Wegovy becomes Novo Nordisk's 𝐟𝐢𝐟𝐭𝐡 regulatory approval globally.

➤ OASIS 4 trial showed approximately 𝐒𝟕% mean weight loss over 64 weeks.

➤ Placebo group recorded approximately 𝐒𝟑% mean weight loss.

➤ Around 𝐨𝐧𝐞 𝐢𝐧 𝐭𝐡𝐫𝐞𝐞 participants lost 𝐒𝟐𝟎% or more body weight.

➤ EU also approved 𝐖𝐞𝐠𝐨𝐯𝐲 𝟕.𝟐 𝐦𝐠 single-dose injection pen.

➤ Novo Nordisk says the injection delivers approximately 𝐒𝟐𝟏% weight loss.

➤ Company plans additional global launches in 𝐭𝐡𝐞 𝐬𝐞𝐜𝐨𝐧𝐝 𝐡𝐚𝐥𝐟 𝐨𝐟 𝟐𝟎𝟐𝟔.

👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:

𝐌𝐢𝐤𝐞 𝐃𝐨𝐮𝐬𝐭𝐝𝐚𝐫, president and CEO of Novo Nordisk:

"For many people, a tablet may be a simpler and more acceptable way to start and continue treatment."

$Hims & Hers Health(HIMS.US) | Canaccord maintains 𝐁𝐮𝐲 on 𝐇𝐢𝐦𝐬 & 𝐇𝐞𝐫𝐬, 𝐫𝐚𝐢𝐬𝐞𝐬 𝐏𝐓 𝐭𝐨 $𝟒𝟎 𝐟𝐫𝐨𝐦 $𝟑𝟐

Analyst highlights a solid start to branded weight loss drugs, constructive sales data, and sees Hims as one of Novo's most "voluminous" partners.